Business · 24/10/2016

FDA Extends Comment Period for Generic Drug User Fees and Corrects Notice

The Food and Drug Administration (FDA) is extending the comment period for its public meeting on generic drug user fees and correcting a notice published in the Federal Register. The agency is allowing interested persons an additional 30 days to submit comments on the draft recommendations for the reauthorization of the Generic Drug User Fee Amendments of 2012 (GDUFA).